SCI时时刷

search
Criteria for the translation of radiomics into clinically useful tests
Criteria for the translation of radiomics into clinically useful tests
Computer-extracted tumour characteristics have been incorporated into medical imaging computer-aided diagnosis (CAD) algor...
Brentuximab vedotin improves outcomes
Around 80% of children and young adults with advanced-stage high-risk Hodgkin lymphoma have durable responses to chemother...
Promise with co-administration of CAR T cells
Promise with co-administration of CAR T cells
Disease relapse in paediatric patients with B cell acute lymphoblastic leukaemia (B-ALL) receiving CD19-targeted chimeric ...
PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching
PADA-1 is the first trial to demonstrate benefit from a treatment-switching strategy guided by active monitoring of ESR1 m...
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data
The first phase III trial to test perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma yie...
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs) specific for CD19 or B cell mat...
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). Ho...
Barriers in access to oncology drugs — a global crisis
Barriers in access to oncology drugs — a global crisis
In the past decade, oncologists worldwide have seen unprecedented advances in drug development and approvals but have also...
DREAMseq of therapy for BRAF-mutant melanoma
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Bemarituzumab enters the FIGHT
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
From WCC 2022
In October 2022, delegates from 120 countries attended the World Cancer Congress (WCC) in Geneva. As the ...
Targeting drugs to tumours using cell membrane-coated nanoparticles
Targeting drugs to tumours using cell membrane-coated nanoparticles
Traditional cancer therapeutics, such as chemotherapies, are often limited by their non-specific nature, causing harm to n...
Towards clinical translation of FLASH radiotherapy
Towards clinical translation of FLASH radiotherapy
The ultimate goal of radiation oncology is to eradicate tumours without toxicity to non-malignant tissues. FLASH radiother...
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Neuroendocrine neoplasms (NENs) can develop in almost any organ and span a spectrum from well-differentiated and indolent ...
GPRC5D-CAR T cells active in MM
BCMA-targeted chimeric antigen receptor (CAR) T cells induce high objective response rates (ORRs) in patients with relapse...
Benefit with neoadjuvant pembrolizumab
Patients with muscle-invasive bladder carcinoma (MIBC) typically receive cisplatin-based chemotherapy prior to radical cys...
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Systemic therapy for early-stage breast cancer: learning from the past to build the future
The treatment of breast cancer has improved dramatically over the past century, from a strictly surgical approach to a coo...
Allogeneic CAR T cells show promise
Several chimeric antigen receptor (CAR) T cell constructs are approved for patients with B cell malignancies. These have t...
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC
A high tumour mutational burden (≥10 mutations per megabase) is a companion biomarker in the histology-agnostic appr...
Mitigating acute chemotherapy-associated adverse events in patients with cancer
Mitigating acute chemotherapy-associated adverse events in patients with cancer
Despite the enthusiasm surrounding novel targeted agents and immunotherapies, chemotherapy remains the mainstay treatment ...
Clinical implications of T cell exhaustion for cancer immunotherapy
Clinical implications of T cell exhaustion for cancer immunotherapy
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T cells are pivotal to the efficacy o...
Activity of selpercatinib in RET fusion-positive cancers confirmed
RET fusions are driver alterations found in several solid tumour types, including thyroid cancer subsets (5–10%), non-smal...
The multiple roles of LDH in cancer
The multiple roles of LDH in cancer
High serum lactate dehydrogenase (LDH) levels are typically associated with a poor prognosis in many cancer types. Even th...
Novel combination delivers prolonged OS
Patients with advanced-stage urothelial carcinoma (UC) typically receive cisplatin-based chemotherapy, which confers a med...
Benefit with ESCAT-guided treatment
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Laparoscopic TME is non-inferior
Despite advances in total neoadjuvant therapy, most patients with rectal cancers continue to require total mesorectal exci...
From ESMO 2022
From ESMO 2022
In early September 2022, the oncology community was able to resume one of their most awaited annual in-pe...
New PEARLS of adjuvant wisdom
In 2021, the FDA approved atezolizumab as an additional treatment following adjuvant chemotherapy for patients with comple...
Towards precision oncology with patient-derived xenografts
Towards precision oncology with patient-derived xenografts
Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive mechanisms that make static interrog...
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major hurdle to effective treatment. Evi...